Oppenheimer has lowered its price target for Abbott Laboratories (NYSE:ABT) to $115 from $132 while maintaining an Outperform rating on the stock, according to a recent analyst note reported by financial news outlets. The adjustment follows the company’s latest quarterly results and reflects a more cautious near-term outlook despite continued confidence in Abbott’s long-term strategic initiatives.
The revised target suggests approximately 10.65% upside potential from Abbott’s share price as of late September 2024, when the average one-year price target stood at $126.84, according to data compiled by Fintel. Oppenheimer’s analysis indicates that while near-term headwinds persist—particularly in non-medical technology segments—the firm anticipates easier year-over-year comparisons in fiscal 2026 and a gradual improvement in top-line growth, projecting low-double-digit increases alongside stabilizing EBIT margins.
This development comes amid a broader trend of reassessments across Wall Street regarding Abbott’s near-term performance. Earlier in October 2024, Oppenheimer had initiated coverage of Abbott Laboratories with an Outperform recommendation and a $140 price target, citing confidence in the company’s Volt pulsed field ablation system and future glucose-ketone monitoring technology as potential catalysts for second-half 2025 growth. At that time, the firm noted subdued uptake of rival systems like Varipulse/CARTO and Farapulse/Opal despite price parity, which bolstered its optimism regarding Abbott’s competitive positioning in electrophysiology.
More recently, other major financial institutions have also adjusted their views on Abbott. Bank of America lowered its price target citing concerns over growth trajectory, while Benchmark adjusted its target to $120. Meanwhile, Leerink Partners maintained its Market Perform rating on the stock, indicating a neutral stance amid mixed signals from the healthcare sector.
Abbott Laboratories, a diversified global healthcare company headquartered in Abbott Park, Illinois, continues to operate across four primary segments: branded generic pharmaceuticals, medical devices, diagnostics, and nutrition products. The company has been actively pursuing innovation in areas such as cardiovascular care—particularly through its Volt system for treating atrial fibrillation—and diabetes care, including its integration with Tandem Diabetes Care’s insulin pumps via a dual glucose-ketone sensor platform.
Institutional ownership data shows that as of September 2024, approximately 3,951 funds or institutions held positions in Abbott Laboratories, representing a slight decrease of 0.78% from the prior quarter. Despite this, average portfolio weight among institutional investors increased to 0.47%, up nearly 10% from the previous period, suggesting continued confidence among long-term holders. Major stakeholders include Capital International Investors and Capital Research Global Investors, which held 4.13% and 3.29% of outstanding shares, respectively.
The put/call ratio for Abbott stock stood at 1.02 as of late September 2024, indicating a marginally bearish sentiment among options traders. However, Oppenheimer’s maintained Outperform rating suggests that the firm views the current valuation as attractive relative to the company’s fundamentals and pipeline of upcoming product approvals.
Looking ahead, Abbott is expected to provide further updates on its financial performance and strategic initiatives during its next quarterly earnings release. Investors will be watching closely for progress on cost optimization efforts, the regulatory trajectory of the Volt PMA application, and adoption rates of its integrated diabetes monitoring solutions. Official filings and statements can be accessed through Abbott’s investor relations website and the U.S. Securities and Exchange Commission’s EDGAR database.
For readers seeking to understand the implications of these analyst adjustments, We see important to recognize that price target revisions reflect evolving assessments of near-term catalysts and macroeconomic pressures rather than fundamental changes to a company’s long-term value. Abbott’s diversified business model and history of consistent dividend payments continue to support its appeal among defensive equity investors, even as short-term forecasts undergo periodic recalibration.
Stay informed about developments affecting Abbott Laboratories and other major healthcare companies by following trusted financial news sources and reviewing official company disclosures as they become available.